Partnerships, Licensing, Investments and M&A Deals and Trends for October 2016 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for October 2016 in Pharmaceuticals


  • Products Id :- GDPH0504MD
  • |
  • Pages: 97
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Partnerships, Licensing, Investments and M&A Deals and Trends for October 2016 in Pharmaceuticals

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for October 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in October 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 8

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, October 2016 12

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, October 2016 14

2.2.1 Samsung Biologics Raises USD2.03 Billion in IPO 14

2.2.2 ConvaTec Raises USD1.8 Billion in IPO 14

2.2.3 China Resources Pharma Raises USD1.8 Million in IPO 15

2.2.4 Allergan Enters into Licensing Agreement with AstraZeneca 16

2.2.5 Astellas Pharma to Acquire Ganymed Pharma 17

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, October 2016 18

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, October 2016 19

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20

3.1 Pharmaceuticals & Healthcare, Global, M&A, October 2016 20

3.1.1 Top M&A Deals in October 2016 21

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, May 2016-October 2016 22

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, October 2016 23

3.2.1 Top Equity Offering Deals in October 2016 24

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, May 2016-October 2016 25

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, October 2016 27

3.3.1 Top PE/VC Deals in October 2016 28

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, October 2016 29

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, October 2016 30

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, May 2016-October 2016 31

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2016-October 2016 32

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2016 33

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, May 2016-October 2016 35

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), October 2016 36

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, October 2016 37

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2016-October 2016 38

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, May 2016-October 2016 40

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), May 2016-October 2016 41

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2016-October 2016 43

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2016 45

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2016 45

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2016 47

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), May 2016-October 2016 49

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), May 2016-October 2016 51

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), May 2016-October 2016 53

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), May 2016-October 2016 55

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, October 2016 56

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, October 2016 57

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, October 2016 58

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 59

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, October 2016 59

5.1.1 Oncology-Deals of the Month 60

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, October 2016 63

5.2.1 Central Nervous System-Deals of the Month 64

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, October 2016 66

5.3.1 Infectious Diseases-Deals of the Month 67

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, October 2016 69

5.4.1 Cardiovascular-Deal of the Month 70

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, October 2016 71

5.5.1 Immunology-Deals of the Month 72

5.6 Pharmaceuticals & Healthcare, Global, Respiratory Deals, October 2016 74

5.6.1 Respiratory-Deal of the Month 75

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, October 2016 76

5.7.1 Metabolic Disorders-Deal of the Month 77

6 Deal Summary by Geography 79

6.1 Pharmaceuticals & Healthcare, North America Deals, October 2016 79

6.1.1 North America-Deals of the Month 80

6.2 Pharmaceuticals & Healthcare, Europe, Deals, October 2016 82

6.2.1 Europe-Deals of the Month 83

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, October 2016 85

6.3.1 Asia-Pacific-Deals of the Month 86

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, October 2016 87

6.4.1 Rest of the World-Deals of the Month 88

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 90

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, May 2016-October 2016 90

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, May 2016-October 2016 92

8 Further Information 94

8.1 Methodology 94

8.2 About GlobalData 95

8.3 Disclosure information 95

8.4 Disclaimer 96

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), May 2016-October 2016 12

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), October 2016 18

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), October 2016 19

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), May 2016-October 2016 20

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2016-October 2016 22

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), May 2016-October 2016 23

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2016-October 2016 25

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), May 2016-October 2016 27

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2016-October 2016 29

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), October 2016 30

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), October 2016 30

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2016-October 2016 31

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2016-October 2016 33

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2016-October 2016 35

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2016-October 2016 36

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2016-October 2016 38

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2016-October 2016 40

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2016-October 2016 41

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2016-October 2016 43

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), May 2016-October 2016 45

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2016-October 2016 47

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2016-October 2016 49

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2016-October 2016 51

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, May 2016-October 2016 53

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), May 2016-October 2016 53

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), October 2016 55

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), May 2016-October 2016 59

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), May 2016-October 2016 63

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), May 2016-October 2016 66

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), May 2016-October 2016 69

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), May 2016-October 2016 71

Figure 32: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 74

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 76

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), May 2016-October 2016 79

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), May 2016-October 2016 82

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), May 2016-October 2016 85

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), May 2016-October 2016 87

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2016-October 2016 90

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2016-October 2016 92

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 13

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, October 2016 14

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), October 2016 19

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 21

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, October 2016 21

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2016-October 2016 22

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 24

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, October 2016 24

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 26

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 28

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, October 2016 28

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, May 2016-October 2016 29

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), October 2016 31

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2016-October 2016 32

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2016-October 2016 32

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2016-October 2016 34

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2016-October 2016 35

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2016-October 2016 36

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), October 2016 37

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2016-October 2016 39

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2016-October 2016 42

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), May 2016-October 2016 44

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 46

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), May 2016-October 2016 48

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2016-October 2016 50

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), October 2016 52

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2016-October 2016 54

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2016 56

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, October 2016 56

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, October 2016 57

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, October 2016 58

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 60

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 64

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 67

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 70

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 72

Table 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 75

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 77

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 80

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 83

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 86

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), May 2016-October 2016 88

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2016-October 2016 91

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2016-October 2016 93

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

select a license

Single User License
USD 1000 INR 64570
Site License
USD 2000 INR 129140
Corporate User License
USD 3000 INR 193710

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com